Special Section on Optical Diagnostic and Biophotonic Methods from Bench to Bedside

Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics

[+] Author Affiliations
Simon Kaja, Jill D. Hilgenberg, Julie L. Collins, Anna A. Shah, Peter Koulen

University of Missouri, Vision Research Center and Departments of Ophthalmology and Basic Medical Science, Kansas City, School of Medicine, 2411 Holmes Street, Kansas City, Missouri 64108

Debra Wawro, Shelby Zimmerman, Robert Magnusson

Resonant Sensors Incorporated (RSI), 416 Yates Street, NH 518, Arlington, Texas 76010

J. Biomed. Opt. 17(8), 081412 (Jun 14, 2012). doi:10.1117/1.JBO.17.8.081412
History: Received November 30, 2011; Revised May 10, 2012; Accepted May 22, 2012
Text Size: A A A

Abstract.  Ovarian carcinoma has the highest lethality rate of gynecologic tumors, largely attributed to the late-stage diagnosis of the disease. Reliable tools for both accurate diagnosis and early detection of disease onset are lacking, and presently less than 20% of ovarian cancers are detected at an early stage. Protein biomarkers that allow the discrimination of early and late stages of ovarian serous carcinomas are urgently needed as they would enable monitoring pre-symptomatic aspects of the disease, disease progression, and the efficacy of intervention therapies. We compare the absolute and relative protein levels of six protein biomarkers for ovarian cancer in five different established ovarian cancer cell lines, utilizing both quantitative immunoblot analysis and a guided-mode resonance (GMR) bioassay detection system that utilizes a label-free optical biosensor readout. The GMR sensor approach provided highly accurate, consistent, and reproducible quantification of protein biomarkers as validated by quantitative immunoblotting, as well as enhanced sensitivity, and is therefore suitable for quantification and detection of novel biomarkers for ovarian cancer. We identified fibronectin, apolipoprotein A1, and TIMP3 as potential protein biomarkers for the differential diagnosis of primary versus metastatic ovarian carcinoma. Future studies are needed to confirm the suitability of protein biomarkers tested herein in patient samples.

Figures in this Article
© 2012 Society of Photo-Optical Instrumentation Engineers

Citation

Simon Kaja ; Jill D. Hilgenberg ; Julie L. Collins ; Anna A. Shah ; Debra Wawro, et al.
"Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics", J. Biomed. Opt. 17(8), 081412 (Jun 14, 2012). ; http://dx.doi.org/10.1117/1.JBO.17.8.081412


Access This Article
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Book Chapters

Topic Collections

Advertisement
  • Don't have an account?
  • Subscribe to the SPIE Digital Library
  • Create a FREE account to sign up for Digital Library content alerts and gain access to institutional subscriptions remotely.
Access This Article
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).
Access This Proceeding
Sign in or Create a personal account to Buy this article ($15 for members, $18 for non-members).
Access This Chapter

Access to SPIE eBooks is limited to subscribing institutions and is not available as part of a personal subscription. Print or electronic versions of individual SPIE books may be purchased via SPIE.org.